Updating results

Atrial fibrillation: management

In development [GID-NG10100] Expected publication date: 17 September 2020

NICE guideline In development

Atezolizumab with nab-paclitaxel for neoadjuvant treatment of early triple negative breast cancer [ID1574]

In development [GID-TA10531] Expected publication date: 15 December 2021

Technology appraisal guidance In development

Electrical stimulation to improve muscle strength in non-neurological chronic conditions

In development [GID-IPG10135] Expected publication date: 17 June 2020

Interventional procedures guidance In development

Venous thromboembolic diseases (QS update)

In development [GID-QS10142] Expected publication date: 09 February 2021

Quality standard In development

Implanted vagus nerve stimulation for treatment-resistant depression

In development [GID-IPG10133] Expected publication date: 20 May 2020

Interventional procedures guidance In development

Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]

In development [GID-HST10026] Expected publication date: TBC

Highly specialised technologies guidance In development

Neonatal parenteral nutrition

In development [GID-NG10037] Expected publication date: 26 February 2020

NICE guideline In development

Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]

In development [GID-TA10229] Expected publication date: 27 May 2020

Technology appraisal guidance In development

Dupilumab for treating severe asthma [ID1213]

In development [GID-TA10276] Expected publication date: 06 May 2020

Technology appraisal guidance In development

Suspected neurological conditions

In development [GID-QS10082] Expected publication date: 03 July 2020

Quality standard In development

Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]

In development [GID-TA10534] Expected publication date: 11 August 2020

Technology appraisal guidance In development

Subarachnoid haemorrhage due to ruptured aneurysms

In development [GID-NG10097] Expected publication date: 03 February 2021

NICE guideline In development

Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186

In development [GID-TA10289] Expected publication date: TBC

Technology appraisal guidance In development

Enzalutamide for the treatment of hormone refractory prostate cancer TA316

In development [GID-TA10267] Expected publication date: TBC

Technology appraisal guidance In development

LJ TEST

In development [GID-TA10462] Expected publication date: TBC

Technology appraisal guidance In development

Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]

In development [GID-TA10464] Expected publication date: TBC

Technology appraisal guidance In development

Clostridium difficile infection: antimicrobial prescribing

In development [GID-NG10144] Expected publication date: 30 September 2020

Antimicrobial prescribing guideline In development

Minimally invasive radical hysterectomy for early stage cervical cancer

In development [GID-IPG10131] Expected publication date: 18 March 2020

Interventional procedures guidance In development

Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]

In development [GID-TA10342] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429

In development [GID-TA10512] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab-relatlimab for untreated advanced or metastatic melanoma [ID1688]

In development [GID-TA10581] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

In development [GID-TA10583] Expected publication date: TBC

Technology appraisal guidance In development

Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

In development [GID-TA10467] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]

In development [GID-TA10571] Expected publication date: 25 August 2021

Technology appraisal guidance In development

Atezolizumab with paclitaxel for untreated unresectable advanced triple-negative breast cancer [ID2705]

In development [GID-TA10570] Expected publication date: TBC

Technology appraisal guidance In development

Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]

In development [GID-TA10569] Expected publication date: TBC

Technology appraisal guidance In development

Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 3 therapies [ID2701]

In development [GID-TA10568] Expected publication date: TBC

Technology appraisal guidance In development

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]

In development [GID-TA10582] Expected publication date: TBC

Technology appraisal guidance In development

Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]

In development [GID-TA10580] Expected publication date: TBC

Technology appraisal guidance In development

Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]

In development [GID-TA10579] Expected publication date: 21 April 0201

Technology appraisal guidance In development

Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma [ID1685]

In development [GID-TA10578] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]

In development [GID-TA10576] Expected publication date: TBC

Technology appraisal guidance In development

Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

In development [GID-TA10575] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab in combination for untreated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID2700]

In development [GID-TA10574] Expected publication date: TBC

Technology appraisal guidance In development

Maintenance of normo-thermia to improve outcomes following neurological injury

In development [GID-IPG10153] Expected publication date: TBC

Interventional procedures guidance In development

Transcatheter Mitral Valve In Ring (TMVIR) for treating a failing mitral valve repair

In development [GID-IPG10154] Expected publication date: TBC

Interventional procedures guidance In development

Transvaginal laser therapy for urogenital atrophy

In development [GID-IPG10155] Expected publication date: TBC

Interventional procedures guidance In development

Transvaginal laser therapy for stress urinary incontinence

In development [GID-IPG10156] Expected publication date: TBC

Interventional procedures guidance In development

Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596

In development [GID-TA10497] Expected publication date: 11 November 2020

Technology appraisal guidance In development

Looked-after children and young people

In development [GID-NG10121] Expected publication date: 26 April 2021

NICE guideline In development

Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]

In development [GID-TA10585] Expected publication date: TBC

Technology appraisal guidance In development

Budesonide for treating active eosinophilic oesophagitis [ID1202]

In development [GID-TA10372] Expected publication date: 08 July 2020

Technology appraisal guidance In development

Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer [ID1443]

In development [GID-TA10476] Expected publication date: 25 November 2020

Technology appraisal guidance In development

Neonatal parenteral nutrition

In development [GID-QS10087] Expected publication date: 01 February 2021

Quality standard In development

Colorectal cancer (QS update)

In development [GID-QS10141] Expected publication date: 26 January 2021

Quality standard In development

Primary and secondary brain cancers

In development [GID-QS10092] Expected publication date: 26 January 2021

Quality standard In development

Perioperative care

In development [GID-QS10094] Expected publication date: 01 March 2021

Quality standard In development

Neonatal infection (early onset): antibiotics for prevention and treatment

In development [GID-NG10111] Expected publication date: 05 March 2021

NICE guideline In development

Thyroid cancer: assessment and management

In development [GID-NG10150] Expected publication date: 04 April 2022

NICE guideline In development

Shared decision making

In development [GID-NG10120] Expected publication date: 14 April 2021

NICE guideline In development